The makers of the Covishield vaccine, AstraZeneca, have acknowledged for the first time that the vaccine may lead to a rare side effect called Thrombosis with Thrombocytopenia Syndrome (TTS). This comes as the company is being sued in a class action and could result in a significant legal payout. Public health experts explain that TTS is a rare condition that has been observed as a potential adverse effect of certain COVID-19 vaccines, including Covishield. They also stress the importance of early detection and treatment of TTS for recovery, and believe that AstraZeneca's admission could lead to enhanced safety monitoring and regulatory oversight for vaccines.
Covishield Vaccine Raises Concerns with Rare Blood Clot Syndrome
Background
Covishield is a COVID-19 vaccine developed by the Serum Institute of India and licensed by AstraZeneca. It is widely used in many countries around the world, including India, Brazil, Argentina, and the United Kingdom.
Thrombosis with Thrombocytopenia Syndrome (TTS)
In recent months, concerns have emerged about the potential link between Covishield and a rare side effect called Thrombosis with Thrombocytopenia Syndrome (TTS). TTS is a condition characterized by blood clots in unusual locations accompanied by low platelet counts.
AstraZeneca Acknowledges Link
On April 7, 2022, AstraZeneca acknowledged for the first time that its vaccine may lead to TTS. This admission came after the company was sued in a class action lawsuit for allegedly failing to adequately warn about the risk of this side effect.
Public Health Experts React
Public health experts have stressed that TTS is a rare condition, but its association with certain COVID-19 vaccines, including Covishield, has been observed. They emphasize the importance of early detection and treatment of TTS for recovery.
AstraZeneca's admission of the potential link between its vaccine and TTS is expected to lead to enhanced safety monitoring and regulatory oversight for vaccines.
Top 5 FAQs and Answers
1. What is Thrombosis with Thrombocytopenia Syndrome (TTS)?
TTS is a rare condition that involves the formation of blood clots in unusual locations, combined with a low platelet count. It can be life-threatening if not treated promptly.
2. Is TTS associated with all COVID-19 vaccines?
TTS has been observed in association with certain COVID-19 vaccines, including the AstraZeneca vaccine. However, the risk is extremely rare, affecting only a tiny fraction of people who receive the vaccine.
3. What are the symptoms of TTS?
Symptoms of TTS can include sudden onset of severe headache, blurred vision, chest pain, shortness of breath, and swelling or pain in the legs. If you experience any of these symptoms after receiving a COVID-19 vaccine, seek medical attention immediately.
4. What is the treatment for TTS?
TTS is treated with anticoagulants (blood thinners) and intravenous immunoglobulin (IVIG) to manage the blood clotting and platelet deficiency, respectively. Early diagnosis and treatment are critical for recovery.
5. Is it safe to receive the Covishield vaccine?
The Covishield vaccine is safe and effective for most people. The risk of TTS is extremely low, and the benefits of vaccination far outweigh the potential risks. It is important, however, to be aware of the potential side effects and to seek medical attention if you experience any unusual symptoms after vaccination.
The state of Gujarat has taken precautionary measures to handle cases of HMPV, a respiratory virus, after one case was detected in a two-month-old boy two weeks ago. Three civil hospitals in Gandhinagar, Ahmedabad, and Rajkot have created isolation wards with a total of 45 beds to handle any potential health emergency. The health department has also issued an advisory to the public to prevent the spread of the virus. However, according to data from the Indian Council of Medical Research and the Integrated Disease Surveillance Programme, there has been no alarming surge in respiratory illnesses in the country.
The recent detection of the Human Metapneumovirus (HMPV) in India has sparked fears of a potential new outbreak similar to the COVID-19 pandemic. However, medical authorities assure the public that HMPV has been circulating globally for years and is not a new virus. While three cases have been reported in India, there is no need to press the panic button as there has been no unusual surge in respiratory illness cases in the country. Karnataka's Health Minister Dinesh Gundu Rao stresses that this is not the first case of HMPV in India and it is not something new.
As China experiences an outbreak of Human Metapneumovirus, also known as HMPV, health officials in Telangana, India have issued a list of precautions for the public, despite no reported cases in the state. The respiratory virus, which primarily affects children, immunocompromised individuals, and the elderly, can lead to a wide range of symptoms, including mild cold-like illness and more serious respiratory conditions. However, the Indian health agency has assured that there is no cause for alarm and that the country does not need to worry at this time.
Renowned nuclear scientist and key figure in India's nuclear program, Dr. R Chidambaram, passed away at the age of 88. He was known for his contributions to nuclear research and played a significant role in India's nuclear tests and the country's civil nuclear agreement with the United States. His passing marks a significant loss for the scientific community and the country's progress in the field of nuclear technology.
The recent spread of a new virus, human metapneumovirus (HMPV), in China has sparked global concerns, with reports of increasing cases among children under 14. However, Indian health experts and the Union Ministry of Health and Family Welfare have dismissed the possibility of a widespread disruption. This is due to previous knowledge about HMPV and its similarity to respiratory syncytial virus (RSV), a common respiratory pathogen. While HMPV may be a trigger for asthma in infants, it is not as deadly as Covid-19 and there is no reason for alarm yet.
China's disease control authorities have launched pilot systems to monitor and report cases of Human Metapneumovirus (HMPV), which has been linked to a recent flu outbreak. As the country continues to battle this respiratory virus, the World Health Organization calls for transparency and cooperation in researching the origins of COVID-19 to better prevent and prepare for future epidemics. Experts warn that people with weak respiratory health and weakened immune systems, as well as young children and the elderly, are most at risk for HMPV and urge preventive measures such as frequent hand washing and wearing masks.
Amidst growing concerns over the coronavirus outbreak, China confirms an increase in cases of human metapneumovirus (HMPV) among children under 14 years old, especially in northern provinces. HMPV is a respiratory illness similar to the common cold, with symptoms including coughing, runny nose, and sore throat. Health officials are urging the public not to blindly use antiviral drugs to fight HMPV, as there is currently no vaccine against the virus. Antibiotics may be prescribed in extreme cases where HMPV has caused pneumonia and a secondary bacterial infection.
The University Grants Commission (UGC) has announced draft guidelines for introducing skill-based courses and micro-credentials in higher education institutions, aligning with the objectives of the National Education Policy 2020. These courses, including emerging fields such as data analytics and AI, aim to enhance students' employability and support economic growth through a qualified workforce. Feedback on the guidelines will be accepted for the next 30 days, giving students and educators a chance to provide their input.
Indian Space Research Organisation (ISRO) has successfully placed two satellites, weighing 220kg, into a circular orbit of 475 km for a crucial space docking technology demonstration. This mission also included the launch of POEM-4 with 24 payloads from startups, industries, and academia. Scientist S Somanath stated that the docking process is expected to take place on January 7, after operations at ISTRAC Bengaluru from December 31. This mission is a major step towards future space missions for India.
The Indian Space Research Organisation (ISRO) launched the PSLV C60 mission on Monday night, marking a historic moment for the country's space exploration. The mission involved the launch of two spacecraft, which will demonstrate India's capabilities in orbital docking- a crucial technology for future human spaceflight and satellite servicing missions. With this achievement, India joins an elite group of countries with this technology, furthering the country's ambitions to send humans to the Moon and establish its own space station.